A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy.

Trial Profile

A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Luminespib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 06 Jan 2012 Planned initiation date changed from 1 Dec 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top